[1] |
LAN Yu, WANG Fenghua.
Comparison and review of updated guidelines for advanced gastric cancer diagnosis and treatment in 2024: CSCO, NCCN and ESMO
[J]. China Oncology, 2025, 35(2): 219-227.
|
[2] |
SHEN Jie, LIU Wanlin, WANG Zezhou, MU Sibo, MO Miao, ZHOU Changming, YUAN Jing, WANG Yu, ZHENG Ying, JI Qinghai.
Survival and cause-of-death analysis of 55 thousand thyroid cancer cases in China from a large single institution hospital-based cancer registry database
[J]. China Oncology, 2025, 35(1): 68-76.
|
[3] |
LIU Shuai, ZHANG Kai, ZHANG Xiaoqing, LUAN Wei.
An exploratory study on the perioperative treatment of locally advanced gastric cancer with combination of penpulimab, anlotinib and chemotherapy
[J]. China Oncology, 2024, 34(7): 659-668.
|
[4] |
WANG Fei, LIU Pei, HU Nan.
Effect of bevacizumab assisted PD-1 inhibitor on serum miR-20a-5p and miR-515-3p in the treatment of gastric cancer
[J]. China Oncology, 2024, 34(5): 493-500.
|
[5] |
Professional Committee on Gastric Cancer of Shanghai Anticancer Association , Professional Committee on Gastrointestinal Cancer of China Association for Promotion of Health Science and Technology .
Chinese expert consensus on clinical practice of locally advanced gastric cancer invading adjacent organs (2024 edition)
[J]. China Oncology, 2024, 34(5): 517-526.
|
[6] |
SHEN Jie, FENG Xiaoshuang, WEN Hao, ZHOU Changming, MO Miao, WANG Zezhou, YUAN Jing, WU Xiaohua, ZHENG Ying.
Metastasis patterns and survival analysis of 572 patients with metastatic cervical cancer: a hospital-based real world study
[J]. China Oncology, 2024, 34(4): 361-367.
|
[7] |
XU Yonghu, XU Dazhi.
Progress and prospects of gastric cancer treatment in the 21st century
[J]. China Oncology, 2024, 34(3): 239-249.
|
[8] |
WANG Xuefei, ZHOU Peng, TANG Zhaoqing.
New progress and development trend of surgical treatment for gastric cancer
[J]. China Oncology, 2024, 34(3): 250-258.
|
[9] |
XUE Chi, GAO Peng, ZHU Zhi, WANG Zhenning.
Application and challenge of immunotherapy in perioperative therapy of gastric cancer
[J]. China Oncology, 2024, 34(3): 259-267.
|
[10] |
SHEN Jie, WANG Jiangli, WANG Zezhou, MO Miao, ZHOU Changming, YUAN Jing, XU Dazhi, ZHENG Ying.
Survival analysis of 6 737 surgically resected gastric cancer cases in China from a large single institution hospital-based cancer registry database
[J]. China Oncology, 2024, 34(3): 268-277.
|
[11] |
LI Jing, ZHENG Lei, GAO Yu.
Analysis of effects of trastuzumab assisted modified DOF fortnightly regimen on serum tumor markers and survival rate in patients with cisplatin-resistant gastric cancer
[J]. China Oncology, 2024, 34(3): 286-292.
|
[12] |
FENG Huizhi, LIU Jingmei, BU Xiaoqian.
A retrospective study of pembrolizumab combined with XELOX regimen in the treatment of advanced gastric cancer
[J]. China Oncology, 2024, 34(11): 1028-1035.
|
[13] |
SUN Yang, WANG Lian, ZHAO Meng, ZHANG Xiaofeng, GENG Zhijun, WANG Yueyue, SONG Xue, ZUO Lugen, LI Jing, HU Jianguo.
The prognostic value of high expression of FKBP1A in gastric cancer and the regulatory effect of targeted PI3K/AKT on glucose metabolism
[J]. China Oncology, 2023, 33(8): 726-739.
|
[14] |
SUN Chongyuan, ZHAO Dongbing.
The progress and future prospects of the application of circulating tumor DNA in the diagnosis and treatment of gastric cancer
[J]. China Oncology, 2023, 33(8): 782-789.
|
[15] |
KANG Yinnan, CHEN Shun, XIE Youcheng, ZHENG Ying, HE Yujing, LI Chuyi, YU Xiaohui.
Application and research progress of antibody drug conjugates in HER2 positive advanced gastric cancer
[J]. China Oncology, 2023, 33(8): 790-800.
|